Antidepressant developer ATAI raises $43M series B round

With an aim to develop "formerly stigmatized" drugs for mental health disorders, ATAI said it raised $43 million in a series B round.

In January, ATAI Life Sciences AG (Berlin, Germany) acquired Perception Neuroscience, giving it NMDA antagonist arketamine (PCN 101). ATAI intends to begin clinical testing of the therapy this year as a rapid-acting antidepressant...